about
Phenobarbital and neonatal seizures affect cerebral oxygen metabolism: a near-infrared spectroscopy studyQuantitative sleep stage analyses as a window to neonatal neurologic functionDocosahexaenoic acid pretreatment confers neuroprotection in a rat model of perinatal cerebral hypoxia-ischemia.Treatment with docosahexaenoic acid after hypoxia-ischemia improves forepaw placing in a rat model of perinatal hypoxia-ischemiaAn extracorporeal artificial placenta supports extremely premature lambs for 1 week.An Evaluation of Cerebral and Systemic Predictors of 18-Month Outcomes for Neonates With Hypoxic Ischemic EncephalopathyTrends in the Screening and Treatment of Retinopathy of Prematurity.Population pharmacokinetics of unbound hydrocortisone in critically ill neonates and infants with vasopressor-resistant hypotension.Screening Cranial Imaging at Multiple Time Points Improves Cystic Periventricular Leukomalacia Detection.Docosahexaenoic acid augments hypothermic neuroprotection in a neonatal rat asphyxia modelImpact of indolent inflammation on neonatal hypoxic-ischemic brain injury in miceCooling for neonatal hypoxic ischemic encephalopathy: do we have the answer?Population pharmacokinetics of phenobarbital in infants with neonatal encephalopathy treated with therapeutic hypothermia.Current controversies in hypothermic neuroprotection.Technical aspects of starting a neonatal cooling program.Therapeutic hypothermia translates from ancient history in to practice.Systemic complications and hypothermia.NIH Consensus Development Conference statement: inhaled nitric-oxide therapy for premature infants.Management of neonatal morbidities during hypothermia treatment.Effect of Depth and Duration of Cooling on Death or Disability at Age 18 Months Among Neonates With Hypoxic-Ischemic Encephalopathy: A Randomized Clinical Trial.Prenatally diagnosed severe CDH: mortality and morbidity remain high.Use of toxins to disrupt neurotransmitter circuitry in the developing brain.Impact of hands-on care on infant sleep in the neonatal intensive care unit.Cytokines and perinatal brain injury.Bumetanide augments the neuroprotective efficacy of phenobarbital plus hypothermia in a neonatal hypoxia-ischemia model.Phenobarbital augments hypothermic neuroprotection.Attenuation of hypoxia-ischemia-induced monocyte chemoattractant protein-1 expression in brain of neonatal mice deficient in interleukin-1 converting enzyme.AMPA-Induced suppression of oligodendroglial gene expression in neonatal rat brain.The relationship between clinically identifiable intrapartum sentinel events and short-term outcome after therapeutic hypothermia.Early appearance of functional deficits after neonatal excitotoxic and hypoxic-ischemic injury: fragile recovery after development and role of the NMDA receptor.New oligodendrocytes are generated after neonatal hypoxic-ischemic brain injury in rodents.Topiramate extends the therapeutic window for hypothermia-mediated neuroprotection after stroke in neonatal rats.Off-label use of therapeutic hypothermia for infants with hypoxic-ischemic encephalopathy.Plasticity of neurons and glia following neonatal hypoxic-ischemic brain injury in rats.Distribution and severity of hypoxic-ischaemic lesions on brain MRI following therapeutic cooling: selective head versus whole body cooling.The non-competitive AMPA antagonist LY 300168 (GYKI 53655) attenuates AMPA-induced hippocampal injury in neonatal rodents.Subdural hemorrhages associated with antithrombotic therapy in infants with cerebral atrophy.Pulmonary dysfunction and therapeutic hypothermia in asphyxiated newborns: whole body versus selective head cooling.Adenovirus-mediated over-expression of interleukin-1 receptor antagonist reduces susceptibility to excitotoxic brain injury in perinatal rats.Hypoxic-ischemic injury results in acute disruption of myelin gene expression and death of oligodendroglial precursors in neonatal mice.
P50
Q27309813-ACFDDD2A-250C-4A29-82FD-F6D4FD6436EDQ30419475-5FAACF24-3696-4034-A763-59D2159D5A07Q33667312-75F2324E-F28F-4CF7-ABE2-E08FEAFC6883Q34163864-A7525FE7-5AA4-4256-9EC4-FADA1DA43DF7Q35805929-D111C2DD-A638-4082-8DDA-BF86B2A2FF26Q36001669-4090B220-F1FD-4D15-AC2D-5D36C67275EBQ36224167-E4B88683-B737-43D5-AA7C-F9C27C284A32Q36381035-60BD4A17-D288-42BE-BE50-99044EC18D41Q36420658-98C3EB37-5EB8-47E0-80F1-40FE22214BB6Q36486153-34A8B362-2D0F-43DF-B960-81A30915B4FDQ36642899-B5641809-87A6-4828-9A2D-81A635677F28Q36987591-0CCEF5B4-5399-4734-BCEF-E2684F056F19Q37030425-27906291-EB0A-4163-9F63-E83D09B69272Q37039213-94C460D5-6CE2-443A-9E4D-025B8FEB6BA2Q37332114-145206DD-E4EE-43AD-818C-AB1C1847F921Q37583890-8591C83A-171C-4B54-A9A0-B71B643181EAQ37708721-91E449B3-B0F4-49A8-A2EC-19B8D0F9ECC8Q37827272-D27C4EC3-BAFC-4E7C-AF8E-3A2D8D8C6D6DQ38363240-905B8FEF-5AF4-4EB2-BCFC-3D5EE2E68F87Q38374611-0D77AA19-947B-4253-9F1C-98761E644DA7Q38665799-9BA5A00F-15A1-4611-BE25-255539AE09F9Q39470038-326A3FE0-B0A9-413E-934F-A607FE15CEB4Q39642821-2078D3CB-16CB-4637-B434-80C323CDEFACQ41433475-C050E9D7-11C6-48D2-B9B0-DC3E4AC8634CQ41968920-C3387A8B-39E2-4243-ACA5-F19D3E131B0DQ42725654-42007B8D-EB2E-454F-91EB-02F651388EEDQ43619888-4AAD315E-2FC0-473A-8A1D-356EC89CD854Q43823406-9257CD25-D97F-420C-B09F-5CA3264A2435Q43947632-B154A918-CD75-4EF7-BDA8-11FC74B729E0Q44364127-1078E150-89D2-41B6-A415-6A2A8B975303Q44850276-DE29C4BB-C7A8-4CB2-A0B5-57239139E0A4Q44857028-B33FACE1-D7F9-4AE0-8EAA-A27754B770B5Q48193636-E63234F2-CE96-486A-B6DA-806A3BBF4B3EQ48370566-436F3BC6-7315-4773-A583-909F8ECAAD12Q48395021-D65F9D0B-D420-44F0-A5E6-399E91E04AEDQ48590240-C5162A1D-E74A-418F-B999-8BA0B330E6EBQ48610252-593FFC10-D6E8-44D1-89E4-49B354041BA5Q48820696-3409CA9B-F098-4E8A-BA2E-A379E77FFBC2Q48855775-0F28A6F1-0C7F-4636-A51D-A906F9D06F81Q48948985-B7F8F572-911E-462B-A232-52CE1F2FE891
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0003-1320-905X
@en
name
John Barks
@ast
John Barks
@en
John Barks
@es
John Barks
@nl
type
label
John Barks
@ast
John Barks
@en
John Barks
@es
John Barks
@nl
prefLabel
John Barks
@ast
John Barks
@en
John Barks
@es
John Barks
@nl
P106
P1153
7003536760
P31
P496
0000-0003-1320-905X